Vanguard Group Inc ownership in 2CL / BridgeBio Pharma, Inc.

BridgeBio 製藥公司

DE ˙ MUN ˙ US10806X1028

€56.19 ↓ -1.02 (-1.78%)

2026-06-01
分享價格

Security	DE:2CL / BridgeBio Pharma, Inc.
Institution	Vanguard Group Inc
Latest Disclosed Ownership	0 shares
Ownership	0.00%

2026-03-26 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of BridgeBio Pharma, Inc. (DE:2CL). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-07-29 , Vanguard Group Inc had reported owning 16,484,985 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-03-26	2026-03-26	13G/A	16,484,985	0	-100.00	0.00	-100.00
2025-07-29	2025-07-29	13G/A	12,800,294	16,484,985	28.79	8.68	17.93
2024-02-13	2024-02-13	13G/A	10,591,455	12,800,294	20.85	7.36	3.81
2023-02-09	2023-02-09	13G/A	9,331,683	10,591,455	13.50	7.09	11.83
2022-02-09	2022-02-09	13G/A	6,441,312	9,331,683	44.87	6.34	20.76
2021-02-10	2021-02-10	13G		6,441,312		5.25

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-01-29	2025-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	16,862,691	30,632	0.18	1,289,827	47.53	0.0187
2025-11-07	2025-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	16,832,059	347,074	2.11	874,257	22.82	0.0131
2025-08-11	2025-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	16,484,985	1,584,840	10.64	711,822	38.19	0.0115
2025-05-09	2025-03-31	13F	BRIDGEBIO PHARMA	COM	10806X102	14,900,145	-177,770	-1.18	515,098	24.50	0.0093
2025-02-11	2024-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	15,077,915	879,059	6.19	413,738	14.45	0.0072
2024-11-13	2024-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	14,198,856	144,108	1.03	361,503	1.54	0.0065
2024-08-13	2024-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	14,054,748	832,622	6.30	356,007	-12.92	0.0068
2024-05-10	2024-03-31	13F	BRIDGEBIO PHARMA	COM	10806X102	13,222,126	421,832	3.30	408,828	-20.88	0.0081
2024-03-11	2023-12-31	13F/A-1	BRIDGEBIO PHARMA	COM	10806X102	12,800,294	1,524,313	13.52	516,748	73.79	0.0113
2024-02-14	2023-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	12,800,294	1,524,313		516,748		0.0098
2023-12-18	2023-09-30	13F/A-1	BRIDGEBIO PHARMA	COM	10806X102	11,275,981	-409,016	-3.50	297,348	47.95	0.0073
2023-11-14	2023-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	11,275,981	-409,016		297,348		0.0013
2023-08-14	2023-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	11,684,997	-378,259	-3.14	200,982	0.49	0.0048
2023-07-14	2023-03-31	13F/A-1	BRIDGEBIO PHARMA	COM	10806X102	12,063,256	1,471,801	13.90	200,009	147.82	0.0051
2023-05-15	2023-03-31	13F	BRIDGEBIO PHARMA	COM	10806X102	12,063,256	1,471,801		200,009		0.0011
2023-02-10	2022-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	10,591,455	587,184	5.87	80,707	-18.84	0.0022
2022-11-14	2022-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	10,004,271	108,734	1.10	99,442	10.67	0.0029
2022-08-12	2022-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	9,895,537	471,425	5.00	89,851	-6.07	0.0025
2022-05-13	2022-03-31	13F	BRIDGEBIO PHARMA	COM	10806X102	9,424,112	92,429	0.99	95,655	-38.55	0.0023
2022-02-14	2021-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	9,331,683	-103,729	-1.10	155,653	-64.80	0.0035
2021-11-12	2021-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	9,435,412	-1,893,717	-16.72	442,238	-35.97	0.0110
2021-08-13	2021-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	11,329,129	1,987,943	21.28	690,623	20.02	0.0172
2021-05-14	2021-03-31	13F	BRIDGEBIO PHARMA	COM	10806X102	9,341,186	2,899,874	45.02	575,417	25.63	0.0156
2021-02-12	2020-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	6,441,312	146,194	2.32	458,042	93.93	0.0133
2020-11-16	2020-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	6,295,118	508,600	8.79	236,193	25.17	0.0078
2020-08-14	2020-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	5,786,518	3,417,387	144.25	188,698	174.65	0.0067
2020-05-15	2020-03-31	13F	BRIDGEBIO PHARMA	COM	10806X102	2,369,131	228,135	10.66	68,705	-8.44	0.0029
2020-02-14	2019-12-31	13F	BRIDGEBIO PHARMA	COM	10806X102	2,140,996	548,046	34.40	75,042	119.41	0.0026
2019-11-14	2019-09-30	13F	BRIDGEBIO PHARMA	COM	10806X102	1,592,950	1,505,668	1,725.06	34,201	1,352.89	0.0013
2019-08-14	2019-06-30	13F	BRIDGEBIO PHARMA	COM	10806X102	87,282	87,282		2,354		0.0001

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.